These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23902545)

  • 41. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions.
    Marzano AV; Ramoni S; Del Papa N; Barbareschi M; Alessi E
    Lupus; 2008 Apr; 17(4):329-31. PubMed ID: 18413415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
    Miyazawa K
    Rinsho Ketsueki; 2008 Oct; 49(10):1358-67. PubMed ID: 18833920
    [No Abstract]   [Full Text] [Related]  

  • 43. Cutaneous lupus erythematosus: a personal approach to management.
    Callen JP
    Australas J Dermatol; 2006 Feb; 47(1):13-27. PubMed ID: 16405478
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings.
    Sontheimer RD
    Autoimmun Rev; 2005 Jun; 4(5):253-63. PubMed ID: 15990071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
    De Souza A; Strober BE; Merola JF; Oliver S; Franks AG
    J Drugs Dermatol; 2012 Oct; 11(10):1224-6. PubMed ID: 23134988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches.
    Wenzel J; Tüting T
    Exp Dermatol; 2007 May; 16(5):454-63. PubMed ID: 17437489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current treatment of cutaneous lupus erythematosus.
    Werth V
    Dermatol Online J; 2001 Feb; 7(1):2. PubMed ID: 11328623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical manifestations of cutaneous lupus erythematosus.
    Werth VP
    Autoimmun Rev; 2005 Jun; 4(5):296-302. PubMed ID: 15990077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Subacute cutaneous lupus erythematosus based on a study of 15 cases].
    Marschalkó M; Dobozy E; Daróczy J; Gyimesi E; Horváth A
    Orv Hetil; 1989 Dec; 130(49):2623-8. PubMed ID: 2689950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus.
    Piette JC; Sbai A; Francès C
    Lupus; 2002; 11(2):67-70. PubMed ID: 11958580
    [No Abstract]   [Full Text] [Related]  

  • 52. Indian Supreme Court demands clarity on clinical trial approvals.
    Kay M
    BMJ; 2014 Jul; 349():g4383. PubMed ID: 24994706
    [No Abstract]   [Full Text] [Related]  

  • 53. Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.
    Nakajima EC; Lipson EJ; Brahmer JR
    J Clin Oncol; 2019 Oct; 37(30):2714-2718. PubMed ID: 31461381
    [No Abstract]   [Full Text] [Related]  

  • 54. Unmet needs in preventing adverse drug-drug interactions.
    Ratain MJ; Seminerio MJ
    Clin Adv Hematol Oncol; 2013 Aug; 11(8):520-1. PubMed ID: 24518424
    [No Abstract]   [Full Text] [Related]  

  • 55. Adverse drug reactions.
    Wooten J
    South Med J; 2006 Sep; 99(9):915. PubMed ID: 17004521
    [No Abstract]   [Full Text] [Related]  

  • 56. An interview with Raymond L. Woosley.
    Woosley RL
    Trends Pharmacol Sci; 2014 Jul; 35(7):305-7. PubMed ID: 24913995
    [No Abstract]   [Full Text] [Related]  

  • 57. No more denial.
    Prescrire Int; 2016 Mar; 25(169):60. PubMed ID: 27152393
    [No Abstract]   [Full Text] [Related]  

  • 58. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going.
    Risitano AM
    Semin Hematol; 2018 Jul; 55(3):113-117. PubMed ID: 30032746
    [No Abstract]   [Full Text] [Related]  

  • 59. Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?
    Porcu M; Solinas C; Garofalo P; de Azambuja E; Scartozzi M; Willard-Gallo K; Preusser M; Saba L
    Crit Rev Oncol Hematol; 2018 Jun; 126():135-144. PubMed ID: 29759556
    [No Abstract]   [Full Text] [Related]  

  • 60. Molecular Pain Imaging by Nuclear Medicine: Where Does It Stand and Where Is It Going?
    Min JJ
    Nucl Med Mol Imaging; 2016 Dec; 50(4):273-274. PubMed ID: 27994681
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.